MX2018008061A - Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. - Google Patents
Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.Info
- Publication number
- MX2018008061A MX2018008061A MX2018008061A MX2018008061A MX2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A MX 2018008061 A MX2018008061 A MX 2018008061A
- Authority
- MX
- Mexico
- Prior art keywords
- moiety
- cnp
- large carrier
- carrier moieties
- prodrug
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 5
- 229940002612 prodrug Drugs 0.000 title abstract 5
- 125000005647 linker group Chemical group 0.000 abstract 2
- 230000002441 reversible effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16150624 | 2016-01-08 | ||
| EP16179286 | 2016-07-13 | ||
| EP16191458 | 2016-09-29 | ||
| PCT/EP2017/050201 WO2017118693A1 (en) | 2016-01-08 | 2017-01-05 | Cnp prodrugs with large carrier moieties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008061A true MX2018008061A (es) | 2018-08-23 |
Family
ID=57838356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008061A MX2018008061A (es) | 2016-01-08 | 2017-01-05 | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10835578B2 (https=) |
| EP (1) | EP3400020A1 (https=) |
| JP (4) | JP7051686B2 (https=) |
| AU (2) | AU2017205268B2 (https=) |
| CA (1) | CA3007976C (https=) |
| MX (1) | MX2018008061A (https=) |
| WO (1) | WO2017118693A1 (https=) |
| ZA (1) | ZA201804414B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| DK3400019T3 (da) | 2016-01-08 | 2022-10-24 | Ascendis Pharma Growth Disorders As | CNP-prodrugs med bærerbinding ved ringenheden |
| EP3400021A1 (en) * | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| ES3064816T3 (en) | 2016-01-08 | 2026-04-29 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
| KR20190125310A (ko) | 2017-03-10 | 2019-11-06 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 접합체 |
| CN111918665B (zh) * | 2018-03-28 | 2024-11-26 | 阿森迪斯药物肿瘤股份有限公司 | Il-2缀合物 |
| CA3112473A1 (en) | 2018-09-12 | 2020-03-19 | Quiapeg Pharmaceuticals Ab | Releasable glp-1 conjugates |
| MX2021008708A (es) * | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
| KR20230019889A (ko) | 2020-06-03 | 2023-02-09 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 서열 및 이의 용도 |
| JP2023530273A (ja) * | 2020-06-12 | 2023-07-14 | ファーマイン コーポレイション | Ｃ型ナトリウム利尿ペプチド及び癌の処置におけるその方法 |
| WO2023110758A1 (en) * | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| EP4529454A1 (en) | 2022-05-23 | 2025-04-02 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| WO2000018422A1 (fr) | 1998-09-28 | 2000-04-06 | Santen Pharmaceutical Co., Ltd. | Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US8596542B2 (en) * | 2002-06-04 | 2013-12-03 | Hand Held Products, Inc. | Apparatus operative for capture of image data |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| WO2004047871A2 (en) | 2002-11-26 | 2004-06-10 | Nobex Corporation | Modified naturetic compounds, conjugates, and uses thereof |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US8283318B2 (en) | 2006-09-08 | 2012-10-09 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| WO2008067127A2 (en) | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| CN101680287B (zh) * | 2007-04-20 | 2013-12-18 | 国际壳牌研究有限公司 | 用于地下地层的加热系统和用于加热地下地层的方法 |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| JP2010533202A (ja) | 2007-07-11 | 2010-10-21 | エンゾン ファーマシューティカルズ，インコーポレーテッド | 多置換芳香族部分を含むポリマー性薬剤送達システム |
| EP2217620A2 (en) * | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| EP2334335A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| PT2432489T (pt) * | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2011012722A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| WO2011031441A1 (en) * | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| EP2519228A4 (en) | 2009-12-31 | 2013-06-19 | Enzon Pharmaceuticals Inc | POLYMER CONJUGATES FROM AN AROMATIC AMINE WITH COMPOUNDS WITH A CLEANER UREA CONTAINER |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| ES2993140T3 (en) | 2010-04-02 | 2024-12-23 | Amunix Pharmaceuticals Inc | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| EP2566334B1 (en) | 2010-05-05 | 2018-04-18 | Prolynx, LLC | Controlled drug release from solid supports |
| US9221882B2 (en) | 2010-05-21 | 2015-12-29 | Technische Universitat Munchen | Biosynthetic proline/alanine random coil polypeptides and their uses |
| AU2012296951B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | Protein carrier-linked prodrugs |
| MX349950B (es) | 2011-08-12 | 2017-08-22 | Ascendis Pharma As | Profarmacos de treprostinil enlazados a un portador. |
| EP2741778A1 (en) | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| CA2843875C (en) | 2011-08-12 | 2020-01-07 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| CA2843506C (en) | 2011-08-12 | 2020-05-12 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| CA2868925C (en) | 2012-04-25 | 2020-01-21 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| EP2853273A4 (en) | 2012-04-25 | 2016-01-13 | Daiichi Sankyo Co Ltd | PROMOTER FOR BONE REPAIR |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| KR20160118264A (ko) | 2014-02-27 | 2016-10-11 | 다이이찌 산쿄 가부시키가이샤 | 스테로이드제 투여로 유발되는 성장 장해에 대한 의약 |
| US11633487B2 (en) | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| EP3242689A1 (en) * | 2015-01-09 | 2017-11-15 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
| HUE057083T2 (hu) | 2015-12-08 | 2022-04-28 | Biomarin Pharm Inc | C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére |
| ES3064816T3 (en) | 2016-01-08 | 2026-04-29 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| DK3400019T3 (da) | 2016-01-08 | 2022-10-24 | Ascendis Pharma Growth Disorders As | CNP-prodrugs med bærerbinding ved ringenheden |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| US11564974B2 (en) * | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
| MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
-
2017
- 2017-01-05 CA CA3007976A patent/CA3007976C/en active Active
- 2017-01-05 AU AU2017205268A patent/AU2017205268B2/en active Active
- 2017-01-05 WO PCT/EP2017/050201 patent/WO2017118693A1/en not_active Ceased
- 2017-01-05 JP JP2018535304A patent/JP7051686B2/ja active Active
- 2017-01-05 US US16/067,057 patent/US10835578B2/en active Active
- 2017-01-05 EP EP17700618.6A patent/EP3400020A1/en active Pending
- 2017-01-05 MX MX2018008061A patent/MX2018008061A/es unknown
-
2018
- 2018-07-02 ZA ZA2018/04414A patent/ZA201804414B/en unknown
-
2020
- 2020-08-27 US US17/005,272 patent/US20210077584A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/184,561 patent/US11154593B2/en active Active
- 2021-03-01 JP JP2021031431A patent/JP6951597B2/ja active Active
- 2021-11-15 US US17/526,481 patent/US20220296682A1/en not_active Abandoned
-
2022
- 2022-03-01 AU AU2022201416A patent/AU2022201416B2/en active Active
- 2022-03-30 JP JP2022054845A patent/JP7350123B2/ja active Active
-
2023
- 2023-09-12 JP JP2023147381A patent/JP7692454B2/ja active Active
-
2024
- 2024-01-08 US US18/407,324 patent/US20240316153A1/en not_active Abandoned
- 2024-12-19 US US18/986,709 patent/US20250127859A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017205268B2 (en) | 2022-02-17 |
| US20190015481A1 (en) | 2019-01-17 |
| WO2017118693A1 (en) | 2017-07-13 |
| JP7692454B2 (ja) | 2025-06-13 |
| JP2021100937A (ja) | 2021-07-08 |
| US11154593B2 (en) | 2021-10-26 |
| EP3400020A1 (en) | 2018-11-14 |
| JP6951597B2 (ja) | 2021-10-20 |
| JP2022088545A (ja) | 2022-06-14 |
| JP7051686B2 (ja) | 2022-04-11 |
| AU2022201416A1 (en) | 2022-03-24 |
| JP2023175776A (ja) | 2023-12-12 |
| US20240316153A1 (en) | 2024-09-26 |
| US20220296682A1 (en) | 2022-09-22 |
| AU2017205268A1 (en) | 2018-06-07 |
| CA3007976C (en) | 2023-09-26 |
| AU2022201416B2 (en) | 2023-06-01 |
| US20210177942A1 (en) | 2021-06-17 |
| JP7350123B2 (ja) | 2023-09-25 |
| US20250127859A1 (en) | 2025-04-24 |
| JP2019507724A (ja) | 2019-03-22 |
| US10835578B2 (en) | 2020-11-17 |
| ZA201804414B (en) | 2019-04-24 |
| US20210077584A1 (en) | 2021-03-18 |
| CA3007976A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018008061A (es) | Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes. | |
| MX2024008222A (es) | Hidrogeles de acido hialuronico degradables. | |
| WO2015095227A3 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| WO2015095811A3 (en) | Combination therapy with neoantigen vaccine | |
| MX2019001302A (es) | Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas. | |
| NZ710729A (en) | Amatoxin derivatives | |
| EP3566750A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| MX2023002599A (es) | Conjugados de compuestos de tubulisina cuaternizada. | |
| CY1122899T1 (el) | Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη | |
| HK1206297A1 (en) | Pharmaceutical compositions for combination therapy | |
| MX2018001511A (es) | Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos. | |
| MX2023004647A (es) | Copolimeros de dibloque auto-montados compuestos de pegmema y segmentos polimericos que tienen farmaco. | |
| TN2018000393A1 (en) | Pegylated carfilzomib compounds | |
| IN2014DN08299A (https=) | ||
| MY202884A (en) | Compounds useful in hiv therapy | |
| WO2014134457A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2018001733A (es) | Compuestos heterocíclicos de fumagillol y métodos de elaboración y uso de los mismos. | |
| WO2014134486A3 (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| MX2021003186A (es) | Nuevos conjugados de hidrogel. | |
| CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
| WO2014035846A3 (en) | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |